KeraVision
Fremont
About KeraVision
KeraVision engages in the development of a new category of non-laser vision correction products for the treatment of common vision disorders, including myopia, hyperopia, and astigmatism, to offer an alternative to eyeglasses, contact lenses, and other vision correction surgical procedures. Its first product, intacs corneal ring segments, has been approved by the FDA for correcting mild myopia in the range of -1.0 to -3.0 diopters in patients who are 21 years of age or older, who have a stable refraction, and who have up to +1.0 diopter of astigmatism. It is currently conducting a Phase III clinical trial to expand its approved range of indication for myopia to include -0.75 to -1.0 diopter and -3.1 to -4.5 diopters.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Website: keravision.com
- Phone: (510)353-3000
Canonical: https://fsome.com/organization/keravision-2902880 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.